BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3249 related articles for article (PubMed ID: 15663992)

  • 1. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine prevention and treatment of prostate cancer.
    Tammela TL
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):59-67. PubMed ID: 22465099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
    Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H;
    Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D; Giannakopoulos X; Charalabopoulos K; Sofikitis N
    Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New development of endocrine therapy in prostate cancer].
    Naito S
    Gan To Kagaku Ryoho; 1996 May; 23(6):684-8. PubMed ID: 8645018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 163.